Evaluation of pretreatment serum interleukin-6 and tumour necrosis factor alpha as a potential biomarker for recurrence in patients with oral squamous cell carcinoma

• Ivana Skrinjar ^[2] ; Vlaho Brailo ^[1] ; Danica Vidovic-Juras ^[2] ; Vanja Vucicevic-Boras ^[1] ; Aleksandar Milenovic ^[3]
  1. [1] University of Zagreb

     University of Zagreb

     Croacia

     
  2. [2] Clinical Hospital Center Zagreb, Croatia
  3. [3] University Hospital Dubrava Zagreb, Croatia

  Mostrar afiliaciones +
• Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 20, Nº. 4 (julio), 2015
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Background: Oral squamous cell carcinoma (OSCC) constitutes 3 percent of all cancers with predominant occurrence in middle aged and elderly males. Tumour recurrence worsens disease prognosis and decreases quality of life in patients with OSCC. Proinflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α) have been suggested to play a certain role in variety of tumours. The aim of this study was to investigate the relationship of pretreatment serum IL-6 and TNF-α levels on tumour recurrence in patients with OSCC in order to identify potential biomarkers for the early detection of disease recurrence.

    Material and Methods: The patients with newly diagnosed OSCC were treated and followed from the first visit from November 2006 until January 2008. Serum IL-6 and TNF-α concentrations were measured. The records of the patients were re-examined in July 2012 and data were recorded about cancer characteristics and tumour recurrence. Disease free survival was analyzed by Kaplan-Meier survival curves, log rank test and Cox proportional hazards regression.

    Results: Serum IL-6 was shown as an independent risk factor for tumour recurrence.

    Conclusions: Pretreatment serum IL-6 concentration may be a useful biomarker for identification of OSCC patients with increased risk of the disease recurrence.